Literature DB >> 3123367

Co-induction of lymphokine synthesis by the antineoplastic bryostatins.

H Mohr1, G R Pettit, A Plessing-Menze.   

Abstract

The macrocyclic lactone bryostatins, isolated from marine bryozoans, have been found to be strong inhibitors of e.g., the P 388 murine lymphocyte leukemia cell line and in vivo systems. Presently, bryostatin 1 is under preclinical development as a potential anticancer drug, although the bryostatins exhibit some of the same biological effects as the tumor promoting phorbol-12-myristate-13-acetate (PMA), especially activation of protein kinase C in certain cell types. In our experiments, we investigated the influence of bryostatin 1 on the synthesis of interleukin 2 (IL2) and interferon-gamma (IFN-gamma) by ionophore A23187 or mitogen-induced human blood lymphocytes. These results were then compared with those achieved using the two tumor promotors PMA and teleocidin. Our data indicate that bryostatin 1 is comparable to these two other drugs in increasing production of the two lymphokines 10-100-fold. The IL2 and IFN-gamma production kinetics of cultures induced with either A23187/bryostatin 1 or A23187/PMA were practically identical. The general pattern of peptides, however, released from bryostatin 1 coinduced cultures differed from that obtained when PMA was used.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3123367     DOI: 10.1016/S0171-2985(87)80070-0

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  6 in total

1.  Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin.

Authors:  B Sredni; Y Kalechman; M Albeck; O Gross; D Aurbach; P Sharon; S N Sehgal; M J Gurwith; H Michlin
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

2.  Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta.

Authors:  Wing-Yiu Lee; Peter Hampson; Lydia Coulthard; Farrah Ali; Mike Salmon; Janet M Lord; Dagmar Scheel-Toellner
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

3.  A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.

Authors:  Amy C Peterson; Helena Harlin; Theodore Karrison; Nicholas J Vogelzang; James A Knost; John W Kugler; Eric Lester; Everett Vokes; Thomas F Gajewski; Walter M Stadler
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

4.  A phase II study of bryostatin 1 in metastatic malignant melanoma.

Authors:  D J Propper; V Macaulay; K J O'Byrne; J P Braybrooke; S M Wilner; T S Ganesan; D C Talbot; A L Harris
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

5.  A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.

Authors:  S Madhusudan; A Protheroe; D Propper; C Han; P Corrie; H Earl; B Hancock; P Vasey; A Turner; F Balkwill; S Hoare; A L Harris
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

6.  Protein kinase C: an attractive target for cancer therapy.

Authors:  Barbara Marengo; Chiara De Ciucis; Roberta Ricciarelli; Maria A Pronzato; Umberto M Marinari; Cinzia Domenicotti
Journal:  Cancers (Basel)       Date:  2011-02-01       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.